Granules India Limited has signed a landmark MoU with the Telangana government to invest over ₹1,000 crores in expanding peptides manufacturing, CDMO services and oncology production. Announced at the Telangana Rising Global Summit, the expansion is expected to create 2,500–3,000 jobs and strengthen Telangana’s position as a global life sciences hub.
Granules India Limited’s decision to deepen its footprint in Telangana through a landmark Memorandum of Understanding with the state government marks a significant moment for both the company and India’s fast-expanding life sciences ecosystem. Announced during the Telangana Rising Global Summit at Bharat Future City, the agreement signals a planned investment of over ₹1,000 crores aimed at scaling up Granules India’s advanced manufacturing capabilities while reinforcing Telangana’s ambition to emerge as a global hub for pharmaceuticals and healthcare innovation.
The proposed expansion is anchored in high-growth, high-complexity segments of the pharmaceutical value chain. Granules India plans to significantly strengthen its presence in peptides manufacturing, contract development and manufacturing organisation (CDMO) services, and oncology-focused production. These areas are increasingly central to the future of global medicine, driven by the rising prevalence of chronic and complex diseases, the shift towards personalised therapies, and the growing demand for specialised manufacturing partners among global pharmaceutical companies.
For Granules India, the MoU represents a strategic step in its long-term evolution from a bulk drug and formulations-focused company to a diversified, innovation-driven pharmaceutical player. Over the years, the Hyderabad-headquartered company has steadily expanded its capabilities across active pharmaceutical ingredients, finished dosages and now complex therapeutics. By committing substantial capital to next-generation manufacturing in Telangana, Granules is aligning itself with global trends that favour scale, quality, regulatory compliance and technological sophistication.
The focus on peptides manufacturing is particularly noteworthy. Peptides are increasingly used in treatments for metabolic disorders, oncology, cardiovascular diseases and rare conditions, making them one of the fastest-growing segments in the pharmaceutical market. However, peptide production requires specialised infrastructure, advanced chemistry expertise and stringent quality controls. By investing in this space, Granules India is positioning itself to tap into a market that offers higher value and stronger growth potential than traditional small-molecule drugs.
The planned expansion of CDMO services further underlines the company’s intent to integrate more deeply into global pharmaceutical supply chains. As innovator companies look to outsource development and manufacturing to trusted partners, CDMO capabilities have become a critical growth engine. Telangana’s supportive ecosystem, skilled talent pool and regulatory-friendly environment offer an ideal platform for Granules India to attract international clients seeking reliable and scalable manufacturing solutions.
Oncology-focused production is another key pillar of the expansion, reflecting both medical need and market opportunity. Cancer therapies are among the most complex and regulated pharmaceutical products, requiring specialised facilities and expertise. Strengthening oncology manufacturing not only enhances Granules India’s portfolio but also aligns with global efforts to improve access to affordable cancer medicines, particularly in emerging markets.
Beyond its corporate implications, the investment carries significant economic and social impact for Telangana. The expansion is expected to generate between 2,500 and 3,000 new jobs over the coming years, spanning high-skilled roles in research, manufacturing, quality assurance and engineering, as well as indirect employment across ancillary services. This focus on high-value employment supports the state’s vision of fostering innovation-led growth rather than low-cost manufacturing alone.
State officials have consistently highlighted life sciences as a cornerstone of Telangana’s development strategy, and the Granules India MoU reinforces that narrative. Over the past decade, Telangana has invested heavily in building future-ready infrastructure, streamlining regulatory processes and nurturing industry-academia collaboration. Initiatives such as dedicated pharma clusters, research parks and innovation hubs have helped the state attract both domestic and global pharmaceutical investments.
The announcement at the Telangana Rising Global Summit adds symbolic weight to the agreement. The summit itself has been positioned as a platform to showcase Telangana’s readiness to host global-scale investments across technology, manufacturing and sustainability-driven sectors. By signing the MoU at Bharat Future City, the state underlined its ambition to develop integrated, forward-looking industrial zones that combine advanced infrastructure with urban planning and quality of life.
Industry observers note that Telangana’s ability to attract large investments in complex pharmaceutical manufacturing sets it apart from many competing regions. Factors such as policy stability, proactive governance and a strong talent base have created a virtuous cycle, encouraging existing players to expand while drawing new entrants. Granules India’s decision to commit over ₹1,000 crores reflects confidence not only in its own growth trajectory but also in the state’s long-term competitiveness.
The partnership also highlights a broader shift in India’s pharmaceutical sector towards higher-value manufacturing and innovation. As global supply chains recalibrate and countries seek to reduce dependence on single geographies, India has an opportunity to move up the value curve. Investments in peptides, oncology and CDMO services signal a departure from volume-driven models towards specialised, technology-intensive production that commands greater margins and strategic relevance.
For Granules India, the Telangana expansion is likely to enhance its global standing and resilience. By consolidating advanced capabilities within a supportive ecosystem, the company can better respond to evolving regulatory requirements, customer expectations and technological change. The scale of the investment suggests a long-term commitment, indicating that the facilities envisioned under the MoU are designed not just for immediate demand but for future growth.
From the government’s perspective, the agreement reinforces Telangana’s positioning as a preferred destination for life sciences investments. The projected job creation and focus on advanced manufacturing align with policy priorities around skill development, innovation and inclusive growth. By attracting investments that generate high-quality employment, the state can strengthen its economic base while fostering knowledge-intensive industries.
The MoU also carries implications for India’s broader healthcare landscape. Enhanced domestic capabilities in peptides and oncology manufacturing can improve access to critical medicines and reduce dependence on imports. As healthcare needs grow and treatment paradigms evolve, local manufacturing capacity becomes a strategic asset, supporting both public health objectives and export competitiveness.
As implementation unfolds over the coming years, the success of the partnership will depend on effective coordination between Granules India and the Telangana government. Infrastructure development, regulatory facilitation and talent availability will play crucial roles in translating the MoU into operational reality. However, the strong alignment between the company’s strategic priorities and the state’s policy vision provides a solid foundation.
In an industry marked by rapid change and intense global competition, the Granules India–Telangana partnership stands out as a case study in how industry and government can collaborate to drive innovation-led growth. The ₹1,000-crore investment, the focus on cutting-edge pharmaceutical segments and the promise of thousands of new jobs together signal a future-oriented approach to industrial development. As Telangana continues to position itself on the global life sciences map, agreements such as this underscore the state’s determination to move beyond scale alone and build lasting leadership in advanced healthcare manufacturing.
Discover more from Creative Brands
Subscribe to get the latest posts sent to your email.
